The differential metabolic signature of breast cancer cellular response to olaparib treatment
D. Berardi, Y. Hunter, L. van den Driest, G. Farrell, N. J. Rattray, Z. Rattray
This study identifies cell-line and dose-dependent metabolic changes in breast cancer cells treated with olaparib, highlighting glutamine and lipid metabolism reprogramming and DNA damage foci accumulation.
bioRxiv · Jun 14, 2022Cancer Biology